Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser

Skin Irritation Clinical Trial

Official title:

Cetaphil Daily Facial Cleanser: 200 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01888887
• Other study ID #: GLI.04.SRE.US10236
• Status: Completed
• Phase: N/A
• Start date: December 2012

Study information

• Verified date: June 2013
• Source: Galderma R&D
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Determine if Cetaphil Daily Facial Cleanser is a contact sensitizer or irritant to the skin

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. primary completion date: February 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Not currently under a doctor's care

• Free of dermatological or systemic disorder which would interfere with the results

• Free of any acute or chronic disease

• Will complete a preliminary medical history form and are in general good health

• Can read, understand, and sign informed consent

Exclusion Criteria:

• Under 18 years old

• Currently under doctor's care

• Currently taking any medication

• History of acute or chronic disease

• Diagnosed with chronic skin allergies

• Pregnant or lactating

Related Conditions & MeSH terms

• Skin Irritation

Intervention

Other:
• Cetaphil Daily Facial Cleanser

Locations

Country	Name	City	State
United States	AMA Laboratories	New City	New York

Sponsors (1)

Lead Sponsor	Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	area of erythema and edema to test reaction of skin to product	9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks will be conducted to test the reaction of the skin to the test product	3 consecutive weeks